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Abstract
Background: Human amniotic membrane-derived mesenchymal stem cells (hAMCs) have the potential to reduce heart and
lung fibrosis, but whether could reduce liver fibrosis remains largely unknown.
Methodology/Principal Findings: Hepatic cirrhosis model was established by infusion of CCl4 (1 ml/kg body weight twice a
week for 8 weeks) in immunocompetent C57Bl/6J mice. hAMCs, isolated from term delivered placenta, were infused into the
spleen at 4 weeks after mice were challenged with CCl4. Control mice received only saline infusion. Animals were sacrificed
at 4 weeks post-transplantation. Blood analysis was performed to evaluate alanine aminotransferase (ALT) and aspartate
aminotransferase (AST). Histological analysis of the livers for fibrosis, hepatic stellate cells activation, hepatocyte apoptosis,
proliferation and senescence were performed. The donor cell engraftment was assessed using immunofluorescence and
polymerase chain reaction. The areas of hepatic fibrosis were reduced (6.2%62.1 vs. control 9.6%61.7, p,0.05) and liver
function parameters (ALT 539.66545.1 U/dl, AST 589.76342.8 U/dl,vs. control ALT 139.16138.3 U/dl, p,0.05 and AST
212.36110.7 U/dl, p,0.01) were markedly ameliorated in the hAMCs group compared to control group. The
transplantation of hAMCs into liver-fibrotic mice suppressed activation of hepatic stellate cells, decreased hepatocyte
apoptosis and promoted liver regeneration. More interesting, hepatocyte senescence was depressed significantly in hAMCs
group compared to control group. Immunofluorescence and polymerase chain reaction revealed that hAMCs engraftment
into host livers and expressed the hepatocyte-specific markers, human albumin and a-fetoproteinran.
Conclusions/Significance: The transplantation of hAMCs significantly decreased the fibrosis formation and progression of
CCl4-induced cirrhosis, providing a new approach for the treatment of fibrotic liver disease.
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Introduction
Liver cirrhosis is a common end-stage of a wide variety of
chronic hepatic diseases caused by a variety of factors, such as viral
infections, alcohol, drugs and chemical toxicity [1,2,3,4]. It is often
associated with the loss of functional liver cells, activation of
hepatic stellate cells (HSC), the senescence of hepatocyte cells and
accumulation of extracellular matrix, amongst other detrimental
processes [3,4,5,6]. Major advances have been made in the
prevention, diagnosis, and treatment of liver cirrhosis, including
the use of liver transplantation and artificial liver [7]. However, the
number of patients suffering from liver disease is still increasing,
and the availability of suitable donor livers is shortage. Morbidity
and mortality from liver cirrhosis continue to be an enormous
burden experienced by many individuals, with substantial
economic cost [8,9,10]. Effective therapies to replace liver
transplantation are clearly required.
Cell therapies are capable of complementing or replacing
damaged liver cells. Enthusiasm for adult cell treatment for the
injured liver has already reached the clinical setting, with
physicians in several countries involved in clinical trials using
mainly bone marrow-derived cells [11,12,13,14,15,16]. However,
not all trials get the positive results and these procedures even led
to clinical harm in patients with established chronic liver disease
[15]. Furthermore, harvesting the bone marrow to get cells is an
invasive procedure for patients. Therefore, an ideal cell source to
overcome the disadvantages of bone marrow-derived cells is
clearly needed.
Recently, the multipotent differentiation ability of human
amniotic membrane-derived mesenchymal stem cells (hAMCs)
has been reported and these cells have attracted a lot of attention
as a cell source for cell transplantation therapy [17,18,19]. Similar
to bone marrow-derived cells, hAMCs have limited self-renewal
ability, have low immunogenicity, and can be induced to various
mesenchymal tissues and cells including those of hepatic lineage
[19,20]. Furthermore, unlike bone marrow-derived cells, they can
be obtained non-invasively from the amnion membrane of term
delivered placenta and easily cultured [18]. These characteristics
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16789are clear advantage of hAMCs, making them potentially superior
to bone marrow-derived cells as a cell transplantation source.
Recent research investigating the effects of hAMCs reported a
decreased fibrosis area in infarcted myocardium [19] and a
reduction in fibrosis in lungs of bleomycin injured mice [21].
However, whether hAMCs can be exploited following cell
transplantation to reduce liver fibrosis remains largely unknown.
In the present study, we transplanted hAMCs into immune
competent C57Bl/6J mice with carbon tetrachloride (CCl4)
induced hepatic cirrhosis and showed that hAMCs reduce HSC
activation, protect hepatocyte from apoptosis, promote hepatocyte
proliferation, and reduce hepatic fibrosis. More interesting, we
confirmed hAMCs depressed hepatocyte senescence and differen-
tiate into albumin-expressing or a-fetoprotein–expressing hepato-
cytes.
Materials and Methods
Animals
Four- to 6-week old C57Bl/6J mice were housed in a standard
animal laboratory. They were kept at 23uC ,25uC with a 12-hour
light/dark cycle and allowed standard chow and water ad libitum
until the time of the study. All animal experimental protocols were
approved by the Animal Care and Use Committee of Nanjing
Medical University (Approval ID 2009-08137) and were in
compliance with Guidelines for the Care and Use of Laboratory
Animals, as published by the National Academy Press (NIH
Publication No. 85-23, revised 1996).
hAMCs isolation and cultures
Human term placentas were obtained from healthy women with
verbal consent (because the placentas were discarded) after
caesarean section and processed immediately. The research
procedure was approved by the Ethics Committee of the Nanjing
Medical University. hAMCs were isolated according to the
method previously described [19] with slight modification. Briefly,
the amnion was manually separated from the chorion, washed
extensively in phosphate-buffered saline (PBS) containing 100 U/
ml penicillin and 100 g/ml streptomycin, and cut into small
pieces. The minced amnion was digested with 0.25% trypsin
(Sigma-Aldrich Co., Steinheim, Germany) and collagenase I
(0.75 mg/ml) in Dulbecco’s Modified Eagle’s Medium (DMEM;
Sigma, Irvine, UK) for 70 min at 37uC. The harvested cells were
cultured in DMEM complete medium composed of DMEM
medium supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin and
2 mM L-glutamine (sigma-Aldrich) at 37uC in a humidified
atmosphere with 5% CO2. The passages 3
rd to 7
th cells were used
in this study. To estimate their potential to differentiate into
several tissue lineages, the cells from the amnion were cultured in
adipogenic and osteogenic medium, respectively.
Mouse liver cirrhosis model generation and hAMCs
transplantation
Liver fibrosis was induced with CCl4 according to the previous
report [22]. Mice were injected intraperitoneally (IP) with CCl4
(50% in olive oil, 1 ml/kg, twice a week) for 8 weeks. After final
CCl4 injection at 4 weeks, animals were randomly divided into two
groups: the hAMCs group and saline group (10 mice each group).
One day (24 hours) after the eighth injection of CCl4,1 610
5
hAMCs or same volume of saline as a control were injected into
the spleen under anesthesia with diethyl ether as described
previously [23,24]. No immunosuppressive reagent was given after
the cell transplantation.
At the time of sacrifice, blood was obtained from the aorta for
measurement of liver functions, and the samples were stored at
220uC.
The liver was removed, rinsed with PBS, and divided into four
portions: (a) fixed in 10% buffered formaldehyde formalin and
embedded in paraffin; (b) snap frozen at 270uC for sectioning and
immunohistochemistry; (c) homogenized in appropriate buffer(s)
and aliquots frozen at 270uC for biochemical assays; and (d) snap
frozen at 270uC for DNA isolation.
Assessment of liver functions
Elevations in serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) generally reflect hepatocyte
injury, which were measured by automated biochemical analyzer.
Liver histology and morphometric collagen
determination
The liver paraffin sections (5 mm) were stained with H&E for
histological analysis or Masson trichrome for collagen deposition.
The percentage of fibrotic area in the liver was measured with a
computer-assisted automated image analyzer Image-Pro Plus 5.1
(Media Cybernetics Inc., Bethesda, MD, USA). This analyzer
measured ten random fields per slide and calculated the ratio of
connective tissue to the whole area of the liver.
Quantitation of stellate cells
The activated HSC is a key cell type that contributes to liver
fibrosis [6]. Upon liver damage, HSC become activated and
produce excessive extracellular matrix, leading eventually cirrhosis
and liver failure. To observe whether transplanted hAMCs could
inhibit the activation of HSC, the expression of desmin, alpha-
smooth muscle actin (a-SMA) and glial fibrillary acidic protein
(GFAP) were examined by immunofluorescent staining in
deparaffinized liver sections. The sections were incubated with
primary antibody at 4uC overnight. After the sections were washed
with PBS, they were incubated with secondary antibody, FITC-
labeled goat anti-mouse immunoglobulin G (1:200 dilution; BD
Pharmingen), or Rodamin-labeled goat anti-mouse immunoglob-
ulin G (1:200 dilution; Dako). After they had been washed in PBS,
the sections were mounted with a medium containing 4-,6-
diamidino-2-phenylindole (DAPI) as a counter stain (1:200
dilution, Dako), coverslipped, and examined under a fluorescence
microscope. Cells were counted in the eight fields per slide for each
mouse (magnification 6200).
Measurements of hepatocyte regeneration and
apoptosis
To evaluate hepatocyte regeneration, deparaffinized liver
sections were incubated overnight at 4uC with mouse monoclonal
antibodies against proliferating cell nuclear antigen (PCNA, 1:200
dilution, BD Pharmingen).
To evaluate hepatocyte apoptosis, the terminal deoxynucleotidy
transferase-mediated dUTP nick end-labeling (TUNEL) assay was
performed using an In Situ Cell Death Detection Kit (Roche,
Germany) according to the manufacturer’s instructions.
The PCNA and apoptotic indices were defined by calculating
the number of positive cells per field at 6200 magnification in
each complete liver section.
Measurement of senescence-associated b-gal activity
Detection of Senescence-associated b-Gal staining (SA-b-Gal)
was performed as described previously [25]. SA-b-Gal -positive
were quantified by counting stained and unstained cells and
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total counted cells.
Detection of human cells by DNA-PCR
To determine if hAMCs were present in murine organs, DNA
was extracted from liver using phenol chloroform and amplified by
PCR using primers specific for human Alu repeat sequences. DNA
extracted from healthy mouse liver served as a control.
Measurements of antioxidant activity
The enzymatic activities of superoxide dismutase (SOD) were
measured through xanthine-oxidation method according to the
instructions (Jiancheng Institute, Nanjing, China) as described
previously [26].
Monitoring of implanted hAMCs in injured liver
Additional mouse were used to examine whether transplanted
hAMCs differentiate into hepatocyte in the injured liver. Cells
were labeled with DiI (Molecular Probes Inc., Eugene, USA) for
cell tracking [27,28] according to the manufacturer’s protocol
before the transplantation. Animals were killed 4 weeks after
transplantation. Liver were fixed in 4% paraformaldehyde and
processed for cryosection. Potential transformation to hepatocyte
cells from engrafted hAMCs was verified by antibody immuno-
staining for human albium protein (1:200 dilution, Abcam) and a-
fetoprotein (1:200 dilution, Abcam). FITC-conjugated IgG
antibody (1:400 dilution, BD Pharmingen) was used as a secondary
antibody. All morphometric studies were performed using a
confocal microscope by two experienced technicians blinded to the
treatment.
Western blot analysis
Liver sections were lysed in RIPA buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 1.0 mM sodium orthovanadate, 0.1% sodium
dodecyl sulfate (SDS), 1.0 mM phenylmethyl-sulfonylfluoride,
1.0 mg/ml aprotinin, 10 mg/ml leupeptin, and 1.0 mg/ml pep-
statin A in autoclaved ddH2O) for 30 min on ice. Lysates were
centrifuged (13,000 g, 15 min, 4uC) and supernatants were
collected. Protein lysates (30 mg) were electrophoresed on sodium
dodecyl sulfate-polyacrylamide gels and transferred onto nitrocel-
lulose membranes. After blocking, membranes were incubated
overnight at 4uC with specific antibodies against hepatocyte growth
factor (HGF), p16
INK4a,p 2 1
Cip1,p 2 7
Kkip1, Sirt-1, Prdx-1 and bcl-2
(All from santa cruz). After three 5 min washings, the membranes
were incubated with horseradish peroxidase-conjugated secondary
antibody, washed and visualized with an ECL detection kit
(Amersham Pharmacia, New Jersey, USA).
Statistical analysis
Data are expressed as mean 6 SEM. Statistical analysis was
performed using independent sample-t test. A p-value of ,0.05
was taken to indicate statistical significance.
Results
hAMCs characterization
During the primary cell cultures, the attached cells stretched and
took the shape of a typical spindle-shaped fibroblast phenotype
(Fig. 1A). These adherent cells could be readily expanded in vitro by
successive cycles of trypsinization, seeding and culture every 3 days
for 15 passages without visible morphologic change. At the end of
the induction period, the cells differentiated into adipogenic and
osteogenic lineages (Figs. 1B and C).
hAMCs transplantation ameliorated the CCl4-induced
deterioration of liver function
Mice treated with CCl4 alone had 4-fold increase of serum ALT
(539.66545.1 U/dl) and 2.5-fold increase of serum AST
(589.76342.8 U/dl) activity relative to those with hAMCs group
(ALT 139.16138.3 U/dl, p,0.05 and AST 212.36110.7 U/dl,
p,0.01), respectively. These results suggested that hAMCs transplan-
tation ameliorates the CCl4-induced deterioration of liver function.
hAMCs transplantation alleviated CCl4-induced liver
fibrosis
After 8 weeks of CCl4 challenge, liver fibrosis was observed in
Masson-stained sections. hAMC transplantation had 1.5-fold
decrease of fibrotic area (6.2%62.1 vs. control 9.6%61.7,
p,0.05) and made the thickened septal fibrosis thinning or
disappears (Fig. 2). Thus, hAMC transplantation prevented and
ameliorated the formation of liver fibrosis.
hAMCs transplantation reduced CCl4-induced hepatic
stellate cell activation
After 8 weeks of CCl4 challenge, desmin, a-SMA- and GFAP-
positive HSCs were strongly and diffusely present near the
expanding septa and in the perisinusoidal spaces of sidual hepatic
parenchyma. hAMCs transplantation significantly reduced the
percentages of these positive HSCs [desmin 35.2%65.8, a-SMA
52.3%611.2, GFAP 51.7%612.2 in control group vs. desmin
17.2%63.8, a-SMA 22.3%68.5, GFAP 21.1%69.2 in hAMCs
Figure 1. Characterization of human amniotic membrane-derived mesenchymal stem cells. (A) Human amniotic membrane-derived
mesenchymal stem cells (hAMCs) display fibroblastic morphology in cultures. (B) and (C) The differentiation of hAMCs into adipocytos and
osteoblasts in cultures. Cells were incubated in adipogenic or osteogenic medium and then analyzed by cytochemical staining with Oil Red-O (B) and
Alizarin red (C), respectively.
doi:10.1371/journal.pone.0016789.g001
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protein was obviously lower in hAMCs group compared with
control group (p,0.01). Thus, hAMCs transplantation prevented
and reduced the HSC activation.
hAMCs transplantation suppressed hepatocyte apoptosis
and promoted hepatocyte regeneration
To observe whether the reduction of serum ALT and AST were
associated with reduced hepatocyte apoptosis, TUNEL assay was
performed. Quantification revealed a 70% reduction in TUNUL-
positive hepatocyte-nuclei in hAMCs group (5.2611/field of view)
compared with controls (35.2632/field of view; p,0.05, Fig. 4).
We also investigated whether hAMCs transplantation induced
hepatocyte proliferation. As shown in Fig. 4, few PCNA-positive
hepatocytes were detected in control livers, however, many were
observed in hAMCs group. The number of proliferating liver cells
were increased 4-fold in hAMCs group (1664.3/field of view)
compared with control group (3.863.2/field of view; p,0.05).
Figure 2. hAMCs transplantation reduced hepatic fibrosis. (A) Micrographs of Masson’s trichrome stained liver paraffin sections from control
group and hAMCs group. (B) Fibrotic areas were quantified by computer assisted image analysis. Each value is the mean6SEM of determinations in 8
mice of each group. *p,0.05 compared with control group.
doi:10.1371/journal.pone.0016789.g002
Figure 3. hAMCs transplantation reduced CCl4-induced hepatic stellate cells activation. (A) Micrographs of liver frozen sections from
control group and hAMCs group stained with immunofluorescence for Desmin (left panel), DAPI (middle panel) and merged (right panel).
(B) Micrographs of liver frozen sections from control group and hAMCs group stained with immunofluorescence fora-SMA (left panel), DAPI (middle
panel) and merged (right panel). (C) Micrographs of liver frozen sections from control group and hAMCs group stained with immunofluorescence for
GFAP (left panel), DAPI (middle panel) and merged (right panel). (D) Representative Western blots of liver extracts from control group and hAMCs
group for expression of a-SMA. b-actin was used as an invariant control. (E) a-SMA protein levels relative to b-actin protein level were assessed by
densitometric analysis. Each value is the mean6SEM of determinations in 5 mice of each group. ** p,0.01 compared with control group.
doi:10.1371/journal.pone.0016789.g003
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and the upregulation of bcl-2 is also associated with decrease of
cellular apoptosis. As shown in Fig. 4, the HGF and bcl-2 protein
levels in injured livers were upregulated significantly in hAMCs
group compared with control group. Thus, hAMCs transplanta-
tion prevented hepatocyte apoptosis and ameliorated hepatocyte
proliferation.
hAMCs transplantation suppressed hepatocyte
senescence
To test whether the ameliorated effect of hAMCs transplanta-
tion on the CCl4-induced liver fibrosis was associated with
decreasing hepatocyte senescence, senescence-associated b-Gal
activity was examined. As shown in Fig. 5, intense staining was
observed in the livers from control group, however, senescence-
associated b-Gal activity was seldom detected in the livers from
hAMC group.
The expression of senescence-relative proteins, including
p16
INK4a, p21
Cip1, p27
Kkip1 and Sirt-1 were also examined in
livers. Results showed that the expression of p16
INK4a, p21
Cipl and
p27
Kipl was down-regulated significantly, whereas the expression
of Sirt-1 was up-regulated significantly in hAMCs group compared
with control group (Fig. 5).
To observe whether the anti-senescence role of hAMCs was
associated with enhanced antioxidant activity, the levels of SOD
activity in mouse liver homogenate were analyzed. The results
showed that the levels of SOD activity were raised significantly in
hAMCs group compared with control group (Fig. 5). The protein
expression of Prdx I, a member of the peroxiredoxin family was
also examined and found that it was upregulated in hAMC group
compared with in control group (Fig. 5). Thus, hAMC
transplantation prevented and ameliorated the hepatocyte senes-
cence.
hAMCs engraft in CCl4 injured liver
Four weeks after hAMC transplantation, DiI-labeled cells were
observed around the portal tracts (Fig. 6), in the fibrotic areas and
around inflammatory sites of liver. This result suggests that the
transplanted cells migrated through the blood circulation from the
spleen into the sinusoid and liver parenchymal tissue.
Figure 4. hAMCs transplantation suppressed hepatocyte apoptosis and promoted hepatocyte regeneration. (A) Micrographs of liver
paraffin sections from control group and hAMCs group stained immunohistochemically for TUNEL and PCNA. (B) Representative Western blots of liver
extracts from two groups for expression of HGF and bcl-2. b-actin was used as an invariant control. HGF and bcl-2 protein levels relative to b-actin
protein level were assessed by densitometric analysis. Each value is the mean6SEM of determinations in 8 mice of each group. *p,0.05 compared
with control group.
doi:10.1371/journal.pone.0016789.g004
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and monitoring the hepatic differentiation of hAMCs, human-
specific antibodies with no cross-reactivity to mouse antigens were
used to label the liver-associated markers human albumin and a-
fetoprotein. Four weeks following cell transplantation, the
transplanted DiI-labeled hAMCs were detected and expressed
human a-fetoprotein and albumin in mouse liver sections (Fig. 6).
DNA-PCR for human Alu repeat sequences confirmed the
presence of human cells in the liver of CCl4 treated mice. Thus the
transplanted hAMCs could differentiate into albumin-secreting
hepatocyte-like cells in the damaged liver.
Discussion
The aim of this study was to evaluate the effect of hAMCs
transplantation for the improvement of hepatic fibrosis. The major
findings in our study were as follows: (1) the administration of hAMCs
into CCl4-induced fibrosis mouse by the spleen delayed disease
progression and recovered liver function; (2) hAMCs transplantation
inhibited HSC activation; (3) hAMCs transplantation reduced hepato-
cyte apoptosis and promoted hepatocyte proliferation; (4) hAMCs
transplantation depressed hepatocyte senescence; and (5) transplanted
hAMCs migrated into injured liver and expressed hAlb and hAFP.
Figure 5. hAMCs transplantation suppressed hepatocyte senescence. (A) Micrographs of liver section stained histochemically for SA-b-Gal.
(B) SA-b-Gal positive hepatocytes per field. (C) The levels of SOD activity in mouse liver homogenate from control group and hAMCs group.
(D)Representative Western blots of liver extracts from control group and hAMCs group for expression of p16
INK4a, p21
Cipl, p27
Kipl, Sirt 1 and prdx I
expression in livers from hAMCs group or control group. b-actin was used as an invariant control. (E) p16
INK4a, p21
Cipl, p27
Kipl, Sirt 1 and prdx I protein
levels relative to b-actin protein level were assessed by densitometric analysis. Each value is the mean6SEM of determinations in 8 mice of each
group. FOV=Field of view. *p,0.05 compared with control group.
doi:10.1371/journal.pone.0016789.g005
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collagen in the liver, playing a crucial role in the pathogenesis of
hepatic fibrosis [6]. HSCs activation is the earliest step in hepatic
fibrogenesis, collagen deposition, and progressive fibrosis leading
to cirrhosis. When activated, HSCs transform into myofibroblast-
like cells. Since the first report by Yokoi et al [29], desmin has
frequently been used as a marker of HSCs and reflecting the
proliferation kinetics of HSCs after CCl4 intoxication or bile duct
ligation. In addition, amount of evidences demonstrated that the
expression of a-SMA is a reliable and widely used marker of
activation of HSCs [30,31]. GFAP, firstly considered to be specific
for cells of astroglial lineage, is an alternative indicator for the
activation of HSCs and consequent liver fibrogenesis [32,33]. In
this study, we investigated the effect of hAMCs transplantation on
HSCs activation in CCl4-induced cirrhotic mouse. Our study
showed that hAMCs decreased HSCs activation, as indicated by
decreasing expression of a-SMA, GFAP and desmin.
In response to CCl4 treatment, hepatocyte may undergo
apoptosis in addition to necrosis [34]. In our mouse model under
chronic CCl4 administration, hepatocyte apoptosis was suppressed
with increased anti-apoptotic protein bcl-2 and HGF expression in
the livers by hAMCs transplantation. Apoptosis of hepatocytes is
one of the major promoting factors in the development of liver
fibrosis [35]. Previous study [36] has demonstrated that DNA from
apoptotic hepatocytes acts as an important mediator of HSCs
differentiation and inducing HSCs collagen production, thus
promotes liver fibrogenesis. In this study, significantly suppressed
HSCs activation and less collagen accumulation in hAMC
transplanted mice were observed, which might be contributed in
part to the reduced hepatocyte apoptosis.
Hepatic regeneration is an important component of the
recovery process occurred after liver injury, and the improvement
of hepatocyte proliferating capacity could be of critical importance
in CCl4-induced cirrhosis. In liver regeneration, the existence of
liver specific growth factors has been extensively studied. HGF, as
the most effective mitogen, inhibits liver injury by stimulating
hepatocyte proliferation in addition to protecting hepatocyte from
apoptosis [37,38]. In the present study, we confirmed the hAMCs
transplantation induced higher expression of HGF protein in
CCl4-induced liver injury. In additional to a decreased hepatocyte
apoptosis, we also found a more significant hepatocyte prolifer-
ation in hAMC group relative to control group. Therefore, the
improvement of liver functions by the hAMCs transplantation was
partially contributed to enhancing hepatocyte proliferation.
One of the unique responses of the injured liver is hepatocyte
replication and regeneration. However, somatic cells have a
limited capacity for replication owing to lack of the telomerase
enzyme. Increased hepatocyte senescence has been confirmed in
cirrhosis [39] and has been shown to correlate with the ductular
reaction and portal fibrosis in chronic hepatitis C and with clinical
severity [40]. So far, SA-b-gal activity has been used as a marker of
cellular senescence [25,41]. In this study, profound hepatocyte
senescence was confirmed after CCl4-induce liver injury as SA-b-
gal activity was detected frequently in hepatocyte in CCl4-treated
liver. Whereas, hAMCs transplantation depressed cellular senes-
cence in livers. To the best knowledge of our known, this is the first
report that hAMCs transplantation decreased CCl4-induce cellular
senescence. Evidences strongly support that increased expression
of p16
INK4a and p21
Cip1 are the key steps in the development of
cellular senescence [42,43]. Moreover, the Cdk inhibitor p27
Kip1,
which is involved in several forms of G1check point control, was
also correlated with increased cellular senescence. In consistent
with decrease SA-b-gal activity, the expression of senescence-
relative proteins of p16
INK4a, p21
Cip1 and p27
Kip1 were down-
regulated significantly, whereas the expression of Sirt1 was
upregulated significantly in hAMCs group relative to control
group. NAD-dependent deacetylase Sirt protein play an important
role in the survival of cell. The upregulation of Sirt1 could
Figure 6. hAMCs engraft in CCl4 injured livers. (A) Micrographs of liver frozen sections stained with immunofluorescence for DiI (left panel),
a-fetoprotein (middle panel) and merged (right panel). (B) Micrographs of liver frozen sections stained with immunofluorescence for DiI (left panel),
albumin (middle panel) and merged (right panel). Bars=100 mm.
doi:10.1371/journal.pone.0016789.g006
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[44,45,46]. In addition, oxidant stress has been demonstrated to
inducing cellular senescence and apoptosis [47]. In the present
study, SOD activity, an anti-oxidant enzyme, was noticeable
higher in hAMCs group than control group. Our results also
found that the expression of Prdx 1, a member of the
peroxiredoxin family of antioxidant enzymes, was upregulated
significantly in hAMC group than control group. Taken together,
it seems that hAMCs transplantation decreased CCl4-induced
hepatocyte senescence by depressing oxidant stress, upregulating
Sirt 1 expression and reducing p16
INK4a, p21
Cip1 and p27
Kip1
expression.
Previous studies have demonstrated that hAMCs can differen-
tiate into hepatocyte lineage cells in vitro [20,48]. In our study,
hAMCs were successfully transplanted via spleen into hepatic
cirrhosis model to prevent histopathological changes. These cells
survived and scattered in the liver at 4 weeks after the
transplantation. Moreover, they also differentiate into albumin-
expressing or a-fetoprotein–expressing hepatocyte. Therefore, the
effect of hAMCs on reducing fibrogenesis partially likely relies on
the differentiation of these cells into hepatocytes in vivo.
In summary, these results suggest that hAMCs transplantation
significantly decrease the fibrosis formation and progression of
CCl4-induced cirrhosis, providing a new approach for the
treatment of fibrotic liver disease.
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